ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
US Tech 100
19,430.40
0.14%
Dow Jones
38,834.86
0.15%
Brent Oil
84.645
-0.17%
Bitcoin
65,115.67
-0.04%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Sanofi (SAN) Quote

Sanofi

Sanofi (SAN)

Sagalio Energy Ltd
Sant Uk.10te%
Banco Santander SA
Add to Watchlist
87.86
-0.65
( -0.73% )
Updated: 06:01:04
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
87.86
Bid
87.85
Ask
87.87
Volume
153,232
87.57 Day's Range 88.24
80.60 52 Week Range 104.32
Market Cap
111.138B
Previous Close
88.51
Open
88.00
Last Trade
64
@
87.86
Last Trade Time
06:01:04
Financial Volume
-
VWAP
-
Average Volume (3m)
1,443,381
Shares Outstanding
1,264,803,301
Dividend Yield
8.56%
PE Ratio
20.58
Earnings Per Share (EPS)
4.27
Revenue
43.07B
Net Profit
5.4B

About Sanofi

Sector
Health & Allied Services,nec
Industry
Pharmaceutical Preparations
Website
www.sanofi.com
Headquarters
Paris, Paris, Fra
Founded
1994
Sanofi is listed in the Health & Allied Services sector of the Euronext with ticker SAN. The last closing price for Sanofi was 88.51 €. Over the last year, Sanofi shares have traded in a share price range of 80.60 € to 104.32 €.

Sanofi currently has 1,264,803,301 shares outstanding. The market capitalization of Sanofi is 111.14 € billion. Sanofi has a price to earnings ratio (PE ratio) of 20.58.

SAN Latest News

More News

Sanofi: Information concerning the total number of voting rights and shares – May 2024

Sanofi: Information concerning the total number of voting rights and shares – May 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...

June 12 2024
GlobeNewswire Inc.

Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]

Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]...

June 03 2024
GlobeNewswire Inc.

Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié

Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié Sanofi lance son plan mondial 2024 d’actionnariat salarié Paris, le 31 mai 2024. Sanofi lance Action 2024, son...

May 31 2024
GlobeNewswire Inc.

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for...

May 31 2024
GlobeNewswire Inc.

Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO

Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO Le CHMP recommande l'approbation de Dupixent dans l'UE...

May 31 2024
GlobeNewswire Inc.

Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2

Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2 Point d’actualité sur l’examen...

May 31 2024
GlobeNewswire Inc.

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation   Update on FDA priority review of Dupixent for the treatment of COPD...

May 31 2024
GlobeNewswire Inc.

Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.

Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc. Sanofi finalise l’acquisition d’Inhibrx, Inc. Paris, le 30 mai 2024. Sanofi annonce aujourd’hui la finalisation de son...

May 30 2024
GlobeNewswire Inc.

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma   Sarclisa accepted for FDA priority review for the...

May 27 2024
GlobeNewswire Inc.

Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation

Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une...

May 27 2024
GlobeNewswire Inc.

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMTLComtech Telecommunications Corporation
$ 4.07
(87.56%)
91.43M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.35M
ASNSActelis Networks Inc
$ 2.11
(83.48%)
51.37M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
LRHCLa Rosa Holdings Corporation
$ 1.78
(71.15%)
52.9M
STISolidion Technology Inc
$ 0.6881
(-64.35%)
16.36M
DMTKDermTech Inc
$ 0.1488
(-55.25%)
10.74M
QMCOQuantum Corporation
$ 0.3752
(-51.90%)
3.14M
ZNTLZentalis Pharmaceuticals Inc
$ 4.135
(-50.72%)
21.58M
AWINAERWINS Technologies Inc
$ 1.74
(-47.90%)
1.05M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.35M
NVDANVIDIA Corporation
$ 135.58
(3.51%)
294.32M
MBIOMustang Bio Inc
$ 0.8517
(13.56%)
291.95M
CRKNCrown Electrokinetics Corporation
$ 0.0548
(-17.10%)
92.39M

Discussion

View Full Feed
Rodney5 Rodney5 8 minutes ago
This is the mistake of the JPS Lawyers, Your Honor, I work for JPS Shareholders and these JPS Shareholders don't care about the company or the common shareholders, matter of fact we want the Treasury to cram-down, place the company in receivership or whatever it takes so we can collect Par Value on
FNMA
WhAtEvA1 WhAtEvA1 10 minutes ago
$2.50 will not even be in the conversations the moment interim reports signals significant tumor eliminations in humans. IMO.
RDGL
TheKid5 TheKid5 13 minutes ago
Happy Wednewsday
CLNV
Itchy palm Itchy palm 17 minutes ago
Donald 🤪 old saying don’t throw stones when you live in a glass house 😃
DJT
CaptainObvious CaptainObvious 18 minutes ago
06/19/24 - 1,229,013,505
06/13/24 - 1,226,621,118
06/11/24 - 1,226,070,527
06/06/24 - 1,224,429,027
06/05/24 - 1,216,304,027
06/03/24 - 1,213,231,632
05/30/24 - 1,212,733,785
05/24/24 - 1,212,558,785
05/20/24 - 1,211,119,735
05/10/24 - 1
NWBO
JustJack JustJack 18 minutes ago
Even the CEO said there are no shorts you liar!

Insider, unlawfully pumping this stock.
AITX
Itchy palm Itchy palm 19 minutes ago
Give Donny 🤡 the nuclear codes doesn’t matter he’ll forget anyways 🤪
DJT
sunspotter sunspotter 20 minutes ago
".You must be quite an Happy individual.."

Yep.

And certainly more contented than you should be, knowingly promoting the PKTX criminal conspiracy to defraud the greedy but gullible.
PKTX
Methinks Methinks 20 minutes ago
https://bitcoinist.com/trump-allies-under-siege-crypto-scammers-launch-attacks/
It's getting political - which could be reduced or stopped if Wave was used.
Methinks Methinks 22 minutes ago
https://news.ng/russian-cyberattacks-on-ukrainian-civilian-infrastructure-icc-investigating-for-possible-war-crimes/
Wave could reduce criminality if it was used.
Rodney5 Rodney5 23 minutes ago
Clarence, think about this…

Where is "maximize profits for taxpayers" written in the Charter Act? Specifically, in this provision entitled Fee Limitation of the United States:

Charter act prohibits the commitment fees (Seniors, warrants, variable liquidation preference
FNMA
Methinks Methinks 23 minutes ago
https://www.itpro.com/security/cyber-attacks/nhs-dumfries-and-galloway-alerts-every-household-in-the-region-over-potential-exposure-during-february-cyber-attack
Wouldn't need this if they used Wave.
Wingsjr Wingsjr 23 minutes ago
The reason for the drop is because we are getting ready to run to 2-3 dollars because Biden has Alzheimer’s, Trump will crush him in the debate no matter how much they try to protect Babbling Biden. If Biden can get through the debate without shitting his pants, they will say he won but we all will
FNMA
Alexulf Alexulf 24 minutes ago
AITX Short Squeeze Coming!

https://youtu.be/5WaEiumykLM
AITX
Itchy palm Itchy palm 25 minutes ago
How about during covid Donald 🤡 said to use disinfectant you know like Lysol people actually listened to him causing poison emergency increases 🤪 yes sir give him a cognitive test.
DJT
Real McCoy Real McCoy 27 minutes ago
We’ll see who’s shut down, literally, in real time. Ball is in IEs court.

Sorry, but you’re out 100% and are not on the offensive in any way. “Paid basher” is the dumbest thing ever, made up by someone who lost out and can’t admit it.
extrooper extrooper 29 minutes ago
With the new exchange in Texas run by the very people who spoof and naked short NWBO & others, they will be reinforced in their criminality
NWBO
Number sleven Number sleven 30 minutes ago
Kiwi, The conversation was about the strategy behind the Sherman Act lawsuits. Why do you think they are pressing the issue.
Sleven,
AMRN
Stevie G83 Stevie G83 32 minutes ago
Surprising volume. Maybe someone will run it up
XALL
jaiguruji7 jaiguruji7 33 minutes ago
What are the catalysts that we are waiting on from PVSP management, other than the spin off. Is the company still on track with the spin off. Any information positive or negative will be much appreciated. Thanks
PVSP
Itchy palm Itchy palm 33 minutes ago
Ronnie Johnson 🤪Ronnie Johnson 🤪 or do you mean Ronnie Jackson 🤪 yup definitely a cognitive test is needed 😃
DJT
Patient Ninja Patient Ninja 34 minutes ago
Monkey, Sparky and Boxer. Put your money where your mouths are and tell everyone what's happening and going to happen with GAHC and GES. Ninja and everyone else here and other forums waiting to hear what you have. Let's go, let's hear it!
GAHC
dmb2 dmb2 40 minutes ago
Danish Dude, thx for your advocacy of NWBO and its endeavors. Many laws are based on protection of the rights of the individual or entity from false claims, certainly properly founded. However we all have seen when genius is applied to beat our system, proven to be the best in the world, it can be v
NWBO
Patient Ninja Patient Ninja 41 minutes ago
Accumulaters of GES stock make more when gahc takes off with crypto market over next year without investing any more capital. Less shares equals more demand and higher prices. Developing app for federal approval can be done without GES. They want experience of Johnnie boy. There's no money taking GE
GAHC

Your Recent History

EU
SAN
Sanofi
EU
TTE
TotalEnergies
TSX
CNQ
Canadian Natural Resources
TSX
SU
Suncor Energy
TSX
BNS
Bank of Nova Scotia
TSX
TD
Toronto Dominion Bank
TSX
RY
Royal Bank of Canada
TSX
XIC
S&P TSX Capped Composite...
BOV
BRAP4
BRADESPAR PN
BOV
BBSE3
BB SEGURIDADE ON
BOV
BBDC4
BRADESCO PN
BOV
BBAS3
BANCO DO BRASIL ON
BOV
ABEV3
AMBEV S/A ON
ASX
NAB
National Australia Bank
ASX
ANZ
Australia And New Zealan...
ASX
WBC
Westpac Banking
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved